Newsletter

September 18, 2006

Volume VII, Issue 70

Home Page : www.otcjournal.com
Email Questions or Comments To: editor@otcjournal.com

To OTC Journal Members:

Auriga Labs (OTC BB: ARGA): Moving Quickly To Generate Revenues

ARGA is wasting no time gearing up to get their top line rolling as the post close news today demonstrates. Here's what we know so far. The company markets the Extendryl line of FDA Approved drugs used to treat colds, flu, and allergies. They already enjoy about $7.3 million in annual sales from the Extendryl line.

Last week, ARGA added a new product line. They picked up the rights to market the Levall® Product Line. This is another line of medications used to treat cough, chest congestion and stuffy nose from the common cold, flu, or other breathing illnesses such as sinusitis and bronchitis. The Levall products generated $9.7 million last year.

Now, we are rolling on towards $15 million in annual sales. Today, ARGA announced it has acquired the rights to market a third FDA Approved product. The Aquoral™ Product Line has been acquired from European pharmacuetical manufacturer Laboratoires Carilène.

Aquoral™ is used to treat Xerostomia- I'll bet you never heard of it. Xerostomia is more commonly known as dry mouth. Dry mouth is a common side effect caused by many prescription drugs: it can be caused by autoimmune diseases and as a problematic side-effect of more than 400 prescription medications.

This new product fits the aging Baby Boomer demographic perfectly. It is estimated that 25 million Americans over the age of 65 are currently taking a prescription medication with Xerostomia as a side effect. Aquoral™ is delivered by a mouth spray. Therefore, any doctor prescribing a medication with the side effects can also prescribe Aquoral™ to counteract the effect.

The part I like the most about the news: in the news release the company discloses it is planning a Q1 '07 product launch. 170 sales reps will be engaged in marketing this product in 2007.

First $7.3 million - then the company adds another $10 million- now a third product for '07 could take easily take the company into the $30 milllion range total. Unlike most developmental biotech companies, this one will have real sales and real gross profits to support expansion and product development.

Since the stock is not widely followed yet, it remains at the low end of its trading range. Anything below $2 seems pretty low risk technically. Fundamentally, it has the same risk/reward profile associated with most microcap stocks.

ARGA is postioning for major growth. The stock is not widely followed- yet. Perhaps will end up being a sleeper that when awoken, yields big profits for those who own it before investors know much about it.

Here is today's news for your review:

Press Release Source: Auriga Laboratories, Inc.

Auriga Laboratories Announces Acquisition of Aquoral(TM) Product Line

Monday September 18, 4:01 pm ET

Exclusive Rights to Proprietary Product Expands Brand Portfolio and Targets Potential $1 Billion Xerostomia Marketplace

NORCROSS, Ga.--(BUSINESS WIRE)--Sept. 18, 2006--Auriga Laboratories, Inc. (OTCBB:ARGA - News), a specialty pharmaceutical company driving high-growth revenues through acquisition of valuable brand portfolios and innovative drug development programs, has acquired the exclusive license to market the FDA-cleared Aquoral(TM), a prescription-only product designed to treat the widespread condition xerostomia, representing a potential marketplace estimated at more than $1 billion.

Licensing of the Aquoral(TM) brand furthers Auriga's business plan to capitalize on high-growth opportunities in the pharmaceutical industry through aggressive sales, integrated marketing and application of proprietary in-house drug development capabilities. Aquoral(TM) is an innovative integrated spray device containing a proprietary formulation.

Xerostomia, characterized by dry mouth, affects millions of people worldwide. It can be caused by autoimmune diseases and as a problematic side-effect of more than 400 prescription medications, such as antidepressants. The current size of the prescription marketplace for xerostomia medications is at approximately $54 million, but the wider potential market Aquoral(TM) can target is estimated at more than 300 million prescriptions, or more than $1 billion.

Auriga acquired the Aquoral(TM) license from Laboratoires Carilene, a France-based therapeutics developer, and is contingent upon three payments worth $1.5 million with a supply agreement that includes a 5 percent royalty return.

"Acquiring the license for Aquoral is the latest achievement in our strategic business plan to build a substantial portfolio of revenue generating products," said Philip S. Pesin, Chief Executive Officer of Auriga. "We are committed to combine both organic growth and growth through acquisition to drive the investment value of Auriga. This transaction exemplifies the type of proactive measures we will continue as we execute our business plan."

Auriga has allocated two professional sales teams to spearhead sales of Aquoral(TM). The Company expects to launch the Aquoral product by the first quarter of 2007 with nearly 170 sales representatives promoting the product by the end of the year.

Aquoral(TM) is an FDA-cleared, patented prescription mouth spray device that treats xerostomia (dry mouth), which affects approximately 30 percent of people over 65, and 25 million people in the United States alone. Xerostomia is associated with difficulties in chewing, swallowing, tasting or speaking and can be caused by certain autoimmune diseases like Sjogren's Syndrome and Rheumatoid Arthritis.

About Auriga Laboratories(TM)

Auriga Laboratories(TM) is a specialty pharmaceutical company capitalizing on high-revenue markets and opportunities in the pharmaceutical industry through proactive sales, integrated marketing and advanced in-house drug development capabilities. The Company's high-growth business model combines acquisition of proven brand names, powerful product development strategies and rapidly-growing national sales teams and marketing operations. Auriga acquires valuable brand portfolios that are no longer a strategic focus for large pharmaceutical companies, then capitalizes on untapped marketplace opportunities through brand extension and directed sales/marketing programs. The Company's drug-development pipeline leverages novel material science and advanced drug delivery technologies to produce improved formulations of successful brands to further expand markets, sales and clinical indications for proven, successful products. Auriga's exclusive product portfolio currently includes the Extendryl® and Levall® families of prescription products, indicated for relief of symptoms associated with a range of acute respiratory diseases. Auriga plans to become a fully integrated pharmaceutical company by acquiring its own manufacturing and development capabilities. Moving forward, the Company will seek to acquire and/or in-license additional products and technologies to further grow revenues. For more information, please visit: www.aurigalabs.com. For investor-specific information and resources, visit http://www.trilogy-capital.com/tcp/auriga/. For an informational video overview, visit http://www.trilogy-capital.com/tcp/auriga/video.html. To view current stock quotes and news, visit http://www.trilogy-capital.com/tcp/auriga/quote.html.

Forward-Looking Statements

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from our expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in our documents filed from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Statements regarding the regulatory status and/or regulatory compliance of our products, our ability to secure additional financing, our ability to sustain market acceptance for our products, our dependence on collaborators, our ability to find and execute strategic transactions, or potential exposure to litigation, our exposure to product liability claims, and our prices, future revenues and income and cash flows and other statements that are not historical facts contain predictions, estimates and other forward-looking statements. Although the Company believes that its expectations are based on reasonable assumptions, it can give no assurance that its goals will be achieved and these statements will prove to be accurate. Important factors could cause actual results to differ materially from those included in the forward-looking statements.

Contact:

Auriga Laboratories, Inc.
Philip Pesin, 877-287-4428
investors@aurigalabs.com
or
Financial Communications
Trilogy Capital Partners, Inc.
Paul Karon, 800-592-6067
paul@trilogy-capital.com

Source: Auriga Laboratories, Inc.

Commerce Planet in the BLOG

There was a new BLOG posting today on CPNE. The stock looks absolutely great. I believe it is headed to $2 in pretty short order, and then on to a new all time high. Check today's BLOG posting for my comments.

The BLOG is your opportunity to ask questions and offer comments. I will make an effort to answer every legitimate question. If I don't know the answer, I will contact the management and get the answer. Alternatively, if you have questions you don't want publicly displayed, you can always email me directly at editor@otcjournal.com.

To use the BLOG, simply go to the home page at www.otcjournal.com - the BLOG will scroll down automatically on the right side of your screen. The most current journal entries appear in the middle of your screen. Check back frequently for updates particularly when stocks are moving to overbought or oversold levels in volatile markets.

Subscribe

Information is power and timely information is profitable. Become informed and profit from OTC Journal Profiles and Trading Alerts by becoming a Preferred Member today. There is no cost associated with your email subscription. Add your email address below and make sure to check your email inbox and confirm your opt-in request to start receiving the OTC Journal Email Newsletter on a regular basis.

To ensure newsletter delivery, you can add any additional email addresses you may have to the OTC Journal Member List. Receiving the OTC Journal Newsletter in multiple locations is the best way of making sure you don't miss the next investing or trading opportunity! For web based email addresses, the OTC Journal recommends @yahoo.com or @aol.com for timely and reliable email newsletter delivery.

Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the OTC Journal, simply follow the instructions located at the bottom of every OTC Journal Newsletter Edition.

Disclaimer

The OTCjournal.com Newsletter is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible. Moreover, as detailed below, this publication accepts compensation from certain of the companies which it features. Likewise, this newsletter is owned by MarketByte, LLC. To the degrees enumerated herein, this newsletter should not be regarded as an independent publication.

Go Here to view our compensation on every company we have ever covered, or visit the following web address: http://www.otcjournal.com/disclaimer.html for our full profiles and http://www.otcjournal.com/trading-alerts/disclaimer.html for Trading Alerts. MarketByte LLC has been paid a fee of $50,000 by Auriga Labs for coverage of the company. In addition, Trilogy Capital Partners has pledged 90,000 warrants convertible at $1.90, and 22,500 warrants convertible at $2.50 to MarketByte LLC for coverage of Auriga.

All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.

From time to time MarketByte LLC sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.

The editor, members of the editor's family, and/or entities with which they are affiliated aside from MarketBtye LLC itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. Some of the companies featured in the OTC Journal pay a cash ESP fee to an affiliated technology company ranging from $2,000 to $5,000 per month for internet related technology services.

The Trustee of the MarketByte LLC Defined Benefit and Trust (“the MarketByte Pension Plan”) has invested approximately $140,0000 in Dutchess Private Equities II LP (“the Dutchess Limited Partnership”), a limited partnership in which the MarketByte Pension Plan is a limited partner. The Trustee of the MarketByte LLC Defined Benefit and Trust (“the MarketByte Pension Plan”) has invested approximately $190,0000 in the Longview Fund (“the Longview Limited Partnership”), both limited partnerships in which the MarketByte Pension Plan is a limited partner. No one associated with the MarketByte Pension Plan has any knowledge, information, or control as to any past, present, or future investment activities of the Dutchess Limited Partnership or the Longview Fund. The Dutchess Limited Partnership is one of two hedge funds managed by Dutchess Advisors. Dutchess Advisors and Longview periodically refers companies to MarketByte LLC for possible coverage by one of the MarketByte LLC publications, which publications include The OTCJournal.com Newsletter. Dutchess Advisors or Longview may or may not own shares in the companies that it so refers to MarketByte. MarketByte has no information (outside of information readily accessible to the general public such as SEC filings) as to whether Dutchess Advisors or Longview owns any shares in the companies that it refers to MarketByte LLC. The above relationships should be viewed as a potential and/or actual conflict of interest by shareholders and prospective shareholders of MarketByte LLC client companies.

The profiles, critiques, and other editorial content of the OTCjournal.com may contain statements that appear foward relating to the expected capabilities of the companies mentioned herein.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF THE EDITORS OF OTCjournal.com.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at http://www.sec.govand/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Disclaimer ID:$subst('Recip.userid') Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site. MarketByte LLC's mailing address is 4653 Carmel Mtn Rd Suite 308 #402, San Diego, CA 92130.

You can unsubscribe from this list at any time by Clicking Here. If you are having difficulty removing yourself or wish to change your address please go to http://www.otcjournal.com/opt.html?.